Evaluation of telemedicine medical abortion using a no-test protocol in the Eastern Europe and Central Asian region: Evidence from Ukraine, Uzbekistan, and Azerbaijan

被引:0
作者
Tsereteli, Tamar [1 ]
Platais, Ingrida [1 ,2 ]
Maru, Mahlet [1 ]
Maystruk, Galyna [3 ]
Kurbanbekova, Dilfuza [4 ]
Rzayeva, Gulnara [5 ]
Winikoff, Beverly [1 ]
机构
[1] Gynu Hlth Projects, 215 Lexington Ave,Suite 1702, New York, NY 10016 USA
[2] NYU, Grossman Sch Med, New York, NY USA
[3] Charitable Fdn Women Hlth & Family Planning, Kiev, Ukraine
[4] Womens Wellness Ctr, Tashkent, Uzbekistan
[5] Sci Res Inst Obstet & Gynecol, Baku, Azerbaijan
关键词
Azerbaijan; medical abortion; no-test; telemedicine; Ukraine; Uzbekistan; TO-PATIENT TELEMEDICINE; EXPERIENCE; SERVICE;
D O I
10.1002/ijgo.15708
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo evaluate safety, feasibility, and acceptability of a telemedicine medical abortion service without pre-treatment in-person tests in Ukraine, Uzbekistan, and Azerbaijan.MethodsWe conducted an open-label, prospective, observational clinical study at five clinics in the three countries. Interested and eligible participants scheduled a telemedicine consultation with a study provider by phone or video. Medical abortion pills could be obtained by mail or courier or picked up at the study clinic or a pharmacy. Study providers contacted participants 1 week after mifepristone ingestion to assess abortion outcomes based on symptoms, and 3 weeks later to review the result of an at-home, high-sensitivity, urine pregnancy test. Participants were referred to in-person visit based on symptoms, urine pregnancy test results, or initiative by the participant.ResultsIn all, 300 women participated in the study. Almost all participants received medical abortion medications the same day as their first contact with the study clinic, and the majority (n = 297, 99.0%) did not experience any problems receiving them. All except two women (0.67%) followed provider instructions on administration of medications. The majority of participants had a complete abortion without a procedure (Ukraine: n = 115, 95.8%; Uzbekistan: n = 127, 97.7%; Azerbaijan: n = 49, 98.0%), few had in-person visits (Ukraine: n = 30, 25.0%; Uzbekistan: n = 3, 2.3%; Azerbaijan: n = 4, 8.0%), and most were very satisfied or satisfied with the service (Ukraine: n = 116, 96%; Uzbekistan: n = 128, 98%; Azerbaijan: n = 45, 90%). No serious adverse events occurred.ConclusionTelemedicine medical abortion using the no-test protocol is safe, feasible and acceptable for women in Ukraine, Uzbekistan, and Azerbaijan. Telemedicine medical abortion using a no-test protocol is safe, feasible, and highly acceptable to women in Ukraine, Uzbekistan, and Azerbaijan.
引用
收藏
页码:804 / 809
页数:6
相关论文
共 22 条
[1]   Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study [J].
Aiken, A. R. A. ;
Lohr, P. A. ;
Lord, J. ;
Ghosh, N. ;
Starling, J. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (09) :1464-1474
[2]   Clinical and service delivery implications of omitting ultrasound b efore me dication abortion provide d via direct-to-patient telemedicine and mail in the U.S [J].
Anger, Holly A. ;
Raymond, Elizabeth G. ;
Grant, Melissa ;
Haskell, Sue ;
Boraas, Christy ;
Tocce, Kristina ;
Banks, Joey ;
Coplon, Leah ;
Shochet, Tara ;
Platais, Ingrida ;
Winikoff, Beverly .
CONTRACEPTION, 2021, 104 (06) :659-665
[3]  
[Anonymous], 2022, Abortion Care Guideline
[4]   Miles and days until medical abortion via TelAbortion versus clinic in Oregon and Washington, USA [J].
Beardsworth, Kathleen Marie ;
Doshi, Uma ;
Raymond, Elizabeth ;
Baldwin, Maureen K. .
BMJ SEXUAL & REPRODUCTIVE HEALTH, 2022, 48 (E1) :E38-E43
[5]   Women's experiences of a telemedicine abortion service (up to 12 weeks) implemented during the coronavirus (COVID-19) pandemic: a qualitative evaluation [J].
Boydell, N. ;
Reynolds-Wright, J. J. ;
Cameron, S. T. ;
Harden, J. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (11) :1752-1761
[6]   Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic [J].
Chong, Erica ;
Shochet, Tara ;
Raymond, Elizabeth ;
Platais, Ingrida ;
Anger, Holly A. ;
Raidoo, Shandhini ;
Soon, Reni ;
Grant, Melissa S. ;
Haskell, Susan ;
Tocce, Kristina ;
Baldwin, Maureen K. ;
Boraas, Christy M. ;
Bednarek, Paula H. ;
Banks, Joey ;
Coplon, Leah ;
Thompson, Francine ;
Priegue, Esther ;
Winikoff, Beverly .
CONTRACEPTION, 2021, 104 (01) :43-48
[7]  
Comendant R., 2022, REPROD FEMALE CHILD, V1, P1
[8]   Telemedicine for medical abortion: a systematic review [J].
Endler, M. ;
Lavelanet, A. ;
Cleeve, A. ;
Ganatra, B. ;
Gomperts, R. ;
Gemzell-Danielsson, K. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 (09) :1094-1102
[9]   Acceptability of no-test medical abortion provided via telemedicine during Covid-19: analysis of patient-reported outcomes [J].
Erlank, Chelsey Porter ;
Lord, Jonathan ;
Church, Kathryn .
BMJ SEXUAL & REPRODUCTIVE HEALTH, 2021, 47 (04) :261-268
[10]   Self-administered versus provider-administered medical abortion [J].
Gambir, Katherine ;
Kim, Caron ;
Necastro, Kelly Ann ;
Ganatra, Bela ;
Ngo, Thoai D. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (03)